Complete and long-lasting regression of disseminated multiple skin melanoma metastases under treatment with cyclooxygenase-2 inhibitor.
Experimental and clinical evidence indicates that non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors may have anti-cancer activities. Here we report on a patient with a metastatic melanoma of the leg who experienced a complete and sustained regression of skin metastases upon continuous single treatment with the cyclooxygenase-2 inhibitor rofecoxib. Our observations indicate that the inhibition of cyclooxygenase-2 can lead to the regression of disseminated skin melanoma metastases, even after failure of chemotherapy.
Lejeune
Ferdy J
FJ
Department of Visceral Surgery, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne Switzerland. Ferdy.Lejeune@chuv.ch
Monnier
Yan
Y
Rüegg
Curzio
C
D000368:Aged; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007783:Lactones / Q000627:therapeutic use*; D008545:Melanoma / Q000188:drug therapy* / Q000201:enzymology / Q000556:secondary*; D012074:Remission Induction; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000556:secondary*; D013450:Sulfones / Q000627:therapeutic use*
D052246:Cyclooxygenase 2 Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib